Skin academy: Hair, skin, hormones and menopause - Current status/knowledge on the management of hair disorders in menopausal women

European Journal of Dermatology

Volumn 22, Issue 3, 2012, Pages 310-318

  Blume Peytavi, Ulrike ^a   Atkin, Stephen ^b   Gieler, Uwe ^c   Grimalt, Ramon ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alopecia; Hirsutism; Post menopausal women; Quality of life; Skin disorders

Indexed keywords

ANDROGEN; ANTIANDROGEN; BOTULINUM TOXIN A; CHLORMADINONE ACETATE; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DUTASTERIDE; EFLORNITHINE; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FINASTERIDE; FLUTAMIDE; GONADORELIN ASSOCIATED PEPTIDE DERIVATIVE; ISOFLAVONE DERIVATIVE; METFORMIN; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TOPILUTAMIDE;

ALOPECIA; ANDROGEN SYNTHESIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRY SKIN; ESTROGEN DEFICIENCY; FEMALE PATTERN HAIR LOSS; FRONTAL FIBROSING ALOPECIA; HAIR DISEASE; HAIR LOSS; HAIR TRANSPLANTATION; HIRSUTISM; HORMONAL REGULATION; HORMONE ACTION; HOT FLUSH; HUMAN; LIVER TOXICITY; LOW LEVEL LASER THERAPY; MENOPAUSE; OSTEOPOROSIS; PATHOGENESIS; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SKIN FUNCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ALOPECIA; ANDROGENS; ESTROGENS; FEMALE; HAIR; HAIR DISEASES; HIRSUTISM; HUMANS; LIFE STYLE; MALE; MENOPAUSE; QUALITY OF LIFE; SKIN PHYSIOLOGICAL PROCESSES;

EID: 84863189814     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1692     Document Type: Review

References (111)

1. Hill K. The Demography of Menopause. Maturitas 1996; 23: 113-127.
2. Lund KJ. Menopause and the menopausal transition. Med Clin N Am 2008; 92: 1253-1271.
3. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods NSO. Executive summary: Stages of Reproductive Ageing Workshop (STRAW). Fertil Steril 2001; 76: 874-878.
4. Nelson HD. Menopause. Lancet 2008; 371: 760-70.
5. Al-Azzawi F, Palacios S. Hormonal changes during menopause. Maturitas 2009; 63: 135-137.
6. Bruce D, Rymer J. Symptoms of the menopause. Best Practice & Research. Clin Obstet Gynaecol 2009; 23: 25-32.
7. Deeks AA. Psychological aspects of menopause management. Best Pract Res Clin Endocrinol Metab 2003; 17: 17-31.
8. Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD. Influence of menopause on mood: a systematic review of cohort studies. Climacteric 2007; 10: 448-465.
9. Evidence Based Medicine. www.evidence-based-medicine.co.uk/guidelines. [accessed 17 February 2011].
10. Rosenfield R. Hirsutism. N Engl J Med 2005; 353: 2578-2588.
11. Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 2005; 53: 555-568.
12. Quatresooz P, Pierard-Franchimont C, Gaspard U, Pierard GE. Skin climacteric aging and hormone replacement therapy. J Cosmet Dermatol 2006; 5: 3-8.
13. Mofid A, Seyyed Alinaghi SA, Zandieh S, Yazdani T. Hirsutism. Int J Clin Pract 2007; 62: 433-43.
14. Randall VA. Androgens and hair growth. Dermatol Ther 2008; 21: 314-328.
15. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21: 347-362.
16. Blume-Peytavi U, Gieler U, Hoffmann R, Lavery S, Shapiro J. Unwanted facial hair: affects, effects and solutions. Dermatology 2007; 215: 139-146.
17. Al Robaee A, Al-Zolibani A, Al-Shobaili A, Aslam M. Update on hirsutism. Acta Dermatoven APA 2008; 17: 103-119.
18. Dawber RP. Hirsuties. J Gend Specif Med 2002; 5: 34-42.
19. Rittmaster RS. Hirsutism. Lancet 1997a; 349: 191-195.
20. Shah D, Patel S. Hirsutism. Gynecol Endocrinol 2009; 25: 140-148.
21. Mirmirani P. Hormonal changes in menopause: do they contribute to a "midlife hair crisis" in women? Brit J Dermatol 2011; 165 (Suppl): to be published.
22. Blume-Peytavi U., Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, Reygagne P, Messenger A, the European consensus group. S1 guideline in diagnosis of androgenetic alopecia. Br J Der-matol 2011; 164: 5-15.
23. Chen W, Yang CC, Todorova A, Al Khuzaei S, Chiu HG, Warret WI, Ring J. Hair loss in elderly women. Eur J Dermatol 2010; 20; 145-151.
24. Messenger AG. Hair through the female life cycle. Brit J Dermatol 2011; 165 (Suppl): to be published.
25. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging 2007; 2: 189-199.
26. Blume-Peytavi U, Atkin S, Shapiro J, Lavery et al. European Consensus on the evaluation of women presenting with excessive hair growth. Eur J Dermatol 2009; 19(6):597-602.
27. Wines N, Willsteed E. Menopause and the skin. Australas J Der-matol 2001; 42: 149-160.
28. Blume-Peytavi U. An overview of unwanted female hair. Brit J Dermatol 2011; 165 (Suppl): to be published.
29. Bloch A. Self-awareness during the menopause. Maturitas 2002; 41: 61-68.
30. Deeks AA, McCabe MP. Relationship between menopausal stage and age and quality of relationships with partners, children and friends. Climacteric 1998; 1: 271-278.
31. Housman TS, Derrow AE, Sniveley BM, et al. Women with excessive facial hair: a statistically evaluation and review of impact on quality of life. Cosmet Dermatol 2004; 17: 157-165.
32. Keegan A, Liao LM, Boyle M. Hirsutism: a psychological analysis. J Health Psychol 2003; 8: 327-345.
33. Kitzinger C, Willmott J. The thief of woman-hood: women's experience of polycystic ovarian syndrome. Soc Sci Med 2002; 54: 349-361.
34. Meyer AE, von Zerssen D. About methods for an initial psychosomatic investigation of clinical syndromes (exemplified by a research on the so-called idiopathic hirsutism). Fortschr Psychosom Med 1960; 1: 70-77.
35. Rabinowitz S, Cohen R, Le Roith D. Anxiety and hirsutism. Psychol Rep 1983; 53: 827-830.
36. Sonino N, Fava Ga, Mani E, et al. Quality of life of hirsute women. Postgrad Med J 1993; 69: 186-189.
37. Hilditch JR, Lewis J, Peter A, et al. E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996; 24: 161-175.
38. Bener A, Rizk DE, Shaheen H, Micallef R, Osman N, Dunn EV. Measurement-specific quality-of-life satisfaction during the menopause in an Arabian Gulf country. Climacteric 2000; 3: 43-49.
39. Nisar N, Sohoo NA. Frequency of menopausal symptoms and their impact on the quality of life of women: a hospital based survey. J Pak Med Assoc 2009; 59: 752-756.
40. Mazier A, Farsi N, Mandegarfard M, et al. Unwanted facial hair removal with laser treatment improves quality of life of patients: J Cosmet Laser Ther 2010; 12: 7-9.
41. Raine-Fennig NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am J Clin Dermatol 2003; 4: 371-378.
42. Bensaleh H, Belgnaoui FZ, Douira L, Berbiche L, Senouci K, Hassam B. Skin and menopause. Ann Endocrinol (Paris) 2006; 67: 575-580 [article in French].
43. Sator PG. Skin treatments and dermatological procedures to promote youthful skin. Clin Interv Aging 2006; 1: 51-56.
44. Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMS. Clin Interv Aging 2007; 2:283-297.
45. Phillips TJ, Symons J, Menon S and the HT study group. Does hormone therapy improve age-related skin changes in post-menopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicentre study assessing the effects of norethin-drone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in post-menopausal women. J Am Acad Dermatol 2008; 59: 397-404.
46. Calleja-Agius J, Brincat M. The effect of menopause on the skin and other connective tissues. Gynecol Endocrinol 2011 [Epub ahead of print].
47. Verdier-Sévrain S. Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators. Climacteric 2007; 10:289-297.
48. Buster JE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother 2010; 11: 1489-499.
49. Studd J. Ten reasons to be happy about hormone replacement therapy: a guide for patients. Menopause Int 2010; 16:44-46.
50. LaCroix AZ, Chlebowski RT, Manson JAE, et al. Health Outcomes After Stopping Conjugated Equine Estrogens Among Post-menopausal Women with Prior Hysterectomy. J Amer Med Assoc 2011; 305: 1305-1314.
51. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15:584-603.
52. Dolores M, Molla J, Hidalgo-Mora JJ, Soteras MG. Phytotherapy as alternative to hormone replacement therapy. Front Biosci 2011; S3: 191-204.
53. Nikolaoua D, Gilling-Smith C. Hirsutism. Curr Obstet Gynaecol 2005; 15: 174-182.
54. Sinclair R, Patel M, Dawson TL, et al. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Brit J Dermatol 2011; 165 (Suppl): to be published.
55. Tosti A, Paraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol 2005; 52: 55-60.
56. Rallis E, Gregoriou S, Christofdou E, Rigopoulis D. Frontal fibro-sing alopecia: to treat or not to treat? J Cutan Med Surg 2010; 14: 161-166.
57. Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol 1994; 130:770-774.
58. Dawn G, Holmes SC, Moffat D, Munro CS. Post-menopausal frontal fibrosing alopecia. Clin Exp Dermatol 2003; 28: 43-45.
59. Freeman R. Post menopausal hair growth patterns. (unpublished data 2006) http://www.femalepatient.com/html/arc/sig/meno/articles/031_06_029.asp.
60. Moses R, Theile H, Colagiuri S. Postmenopausal hirsutism: The forgotten face. Aust NZ J Obstet Gynaecol 1994; 34: 500-501.
61. Zargar AH, Wani AI, Masoodi SR, Laway BA, Bashir MI, Sala-huddin M. Epidemiologic and etiologic aspects of hirsutism in Kashmiri women in the Indian subcontinent. Fertil Steril 2002; 77: 674-678.
62. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89: 453-462.
63. Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol 1996; 44: 269-276.
64. Dahlgren E, Hohansson S, Lindstedt G, et al. Women with poly-cystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505-513.
65. Kasperlik-Zaluska AA, Stropinska-Gluszak U, Powolny M. Severe virilisation in a 71-year old acromegalic woman with probable poly-cystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007; 134: 134-135.
66. Pauli S, Lobo RA. Polycystic ovary syndrome after menopause: a case report. J Reprod Med 2004; 49: 491-494.
67. Bühler-Christen A, Tischler V, Diener PA, Brändle M. New onset alopecia and hirsutism in a postmenopausal women. Gynecol Endo-crinol 2009; 25: 324-327.
68. Diab DL, Faiman C, Siperstein AE, Zhou M, Zimmerman RS. Viri-lizing adrenal ganglioneuroma in a woman with subclinical Cushing syndrome. Endocr Pract 2008; 14: 584-587.
69. Kim Y, Marjoniemi VM, Diamon T, Lim A, Davis G, Murrell D. Androgenetic alopecia in a postmenopausal woman as a result of ovarian hyperthecosis. Australas J Dermatol 2003; 44: 62-66.
70. Krug E, Berga SL. Postmenopausal hyperthecosis: functional dys-regulation of androgenesis in climacteric ovary. Obstet Gynecol 2002; 99: 893-897.
71. Marcondes JA, Curi DD, Matsuzaki CN, et al. Ovarian hyperthe-cosis in the context of an adrenal incidentaloma in a postmenopausal woman. Arq Bras Endocrinol Metabol 2008; 52: 1184-1188.
72. Saraf S, Milles J, Moloney M, Ramachandran. Ovarian hyper-thecosis in a postmenopausal woman. Endocrine Abstracts 2008; 16: P129.
73. Bachelot A, Meduri G, Baudin E, Kuttenn F, Touraine P. Hyperan-drogenism in a postmenopausal woman presenting with a metastatic ileum endocrine tumor. Fertil Steril 2004; 81: 675-678.
74. Delibasi T, Erdogan MF, Serinsoz E, Kaygusuz G, Erdogan G, Sertcelik A. Ovarian hilus-cell hyperplasia and high serum testosterone in a patient with postmenopausal virilization. Endocr Pract 2007; 13: 472-475.
75. Herrera JD, Davidson JA, Mestman JH. Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulphate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature. Endocr Pract 2009; 15: 149-152.
76. Sanyal D, Taylor WG, Otter MI. Bilateral thecomata in ovaries with normal ultrasonographic and radiological appearance presenting with postmenopausal hirsutism and virilism. J Obstet Gynaecol 2003; 23: 457-458.
77. Sanz OA, Martinez PR, Guarch RT, Goni MJ, Alcazar JL. Bilateral Leydig cell tumour of the ovary: a rate cause of virilization in postmenopausal patient. Maturitas 2007; 57: 214-216.
78. Siekierska-Hellmann M, Sworczak K, Babinska A, Wojtylak S. Ovarian thecoma with androgenic manifestations in a postmenopausal woman. Gynecol Endocrinol 2006; 22: 405-408.
79. Silva PD, Caplan RH, Virata RL. Diagnosis of a small, andro-genizing Brenner cell tumor in a postmenopausal woman aided by laparoscopic salpingo-oophorectomy. A case report. J Reprod Med 2003; 48: 381-383.
80. Wu DH, McMurtrie DG, Hirsch SD, Johnson CM. Postmenopausal hyperandrogenism caused by a benign cystic teratoma: a case report. J Reprod Med 2008; 53: 141-144.
81. Boehm DU, Munz W, Seufert R, Pollow K. Severe virilization in a postmenopausal woman: a case report. Zentralbl Gynakol 2005; 127: 99-101 [article in German].
82. Braunstein GD. Management of female sexual dysfunction in post-menopausal women by testosterone administration: safety issues and controversies. J Sex Med 2007a; 4: 859-866.
83. Braunstein GD. Safety of testosterone treatment in postmenopau-sal women. Fertil Steril 2007b; 88: 1-17.
84. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005; 12: 496-511.
85. Basaria S, Dobs AS. Safety and adverse effects of androgens: how to counsel patients. Mayo Clin Proc 2004; 79: S25-S32.
86. Gelfand MM. Role of androgens in surgical menopause. Am J Obstet Gynecol 1999; 180: S325-7.
87. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hir-sutism and virilism associated with combined androgen-oestrogen hormone replacement therapy. Obstet Gynecol 1991; 77: 595-598.
88. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1105-1120.
89. Somani H, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatologic Therapy 2008; 21: 376-391.
90. Blume-Peytavi U, Hahn S. Medical treatment of hirsutism. Derma-tologic Therapy 2008; 21: 329-339.
91. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-447.
92. Blume-Peytavi U, Vogt A. Current standards in diagnostics and therapy of hair diseases - hair consultation. JDDG 2011, epub ahead of print.
93. Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J 2008; 14: 1.
94. Vexiau P, Chaspaux C, Boudou P, et al. Br J Dermatol 2002; 146: 992-999.
95. Sinclair R, Wewerinke M, Jolley D. Br J Dermatol 2005; 152:466-473.
96. Trüeb RM. Finasteride treatment of patterned hair loss in normoan-drogenic postmenopausal women. Dermatology 2004; 209: 202-207.
97. Thai KE, Sinclair RD. Finasteride for female androgenetic alopecia. Br J Dermatol 2002; 147: 812-813.
98. Georgala S, Katoulis AC, Befon A, Danopoulou I, Georgala C. Treatment of postmenopausal frontal fibrosing alopecia with oral dutas-teride. J Am Acad Dermatol 2009; 61: 157-158.
99. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010; 28: 611-618.
100. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79: 91-5.
101. Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. JDDG 2011; 9 (Suppl): S1-S57.
102. Prager N, Bickett K, French N, Marcovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002; 8: 143-152.
103. Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006; 13: 185-196.
104. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlove-Wuttke D. Chaste tree (Vitex agnus-castus); pharmacology and clinical indications. Phytomedicine 2003; 10: 348-357.
105. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002; 27: 396-404.
106. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54: 824-844.
107. Koulouri O, Conway GS. Management of hirsutism. BMJ 2009; 338: 823-826.
108. Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycycstic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res 2004; 62: 283-287.
109. Müderris II, Bayram F, Ozcelik B, Güyen M. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endrocrinol 2002; 16: 63-66.
110. Tucker P. Bald is beautiful? The psychosocial impact of alopecia areata. J Health Psychol 2009; 141: 42-51.
111. Borelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas 2010; 66: 333-43.